| Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice |
| Wu, ML; Liu, FL; Sun, J; Li, X ; Qin, JR; Yan, QH; Jin, X; Chen, XW; Zheng, YT; Zhao, JC; Wang, JH
|
| 2022
|
| 发表期刊 | ZOOLOGICAL RESEARCH
 |
| ISSN | 2095-8137
|
| 卷号 | 43期号:3页码:457-468 |
| 摘要 | COVID-19 is an immune-mediated inflammatory disease caused by SARS-CoV-2 infection, the combination of anti-inflammatory and antiviral therapy is predicted to provide clinical benefits. We recently demonstrated that mast cells (MCs) are an essential mediator of SARS-CoV-2-initiated hyperinflammation. We also showed that spike protein-induced MC degranulation initiates alveolar epithelial inflammation for barrier disruption and suggested an off-label use of antihistamines as MC stabilizers to block degranulation and consequently suppress inflammation and prevent lung injury. In this study, we emphasized the essential role of MCs in SARS-CoV-2-induced lung lesions in vivo, and demonstrated the benefits of co-administration of antihistamines and antiviral drug remdesivir in SARS-CoV-2-infected mice. Specifically, SARS-CoV-2 spike protein-induced MC degranulation resulted in alveolar-capillary injury, while pretreatment of pulmonary microvascular endothelial cells with antihistamines prevented adhesion junction disruption; predictably, the combination of antiviral drug remdesivir with the antihistamine loratadine, a histamine receptor 1 (HR1) antagonist, dampened viral replication and inflammation, thereby greatly reducing lung injury. Our findings emphasize the crucial role of MCs in SARS-CoV-2-induced inflammation and lung injury and provide a feasible combination antiviral and anti-inflammatory therapy for COVID-19 treatment. |
| 收录类别 | sci
|
| 语种 | 英语
|
| 文献类型 | 期刊论文
|
| 条目标识符 | http://ir.kiz.ac.cn/handle/152453/13821
|
| 专题 | 科研部门_分子免疫药理学（郑永唐）
|
推荐引用方式
GB/T 7714 |
Wu, ML,Liu, FL,Sun, J,et al. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice[J]. ZOOLOGICAL RESEARCH,2022,43(3):457-468.
|
| APA |
Wu, ML.,Liu, FL.,Sun, J.,Li, X.,Qin, JR.,...&Wang, JH.(2022).Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice.ZOOLOGICAL RESEARCH,43(3),457-468.
|
| MLA |
Wu, ML,et al."Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice".ZOOLOGICAL RESEARCH 43.3(2022):457-468.
|
修改评论